Chronic Wound Opportunity EscharExIs poised to address chronic wound debridement, a large and growing market. Given peer consensus supporting early, biologically active debridement and MediWound’s EscharEx Phase III progress, there is a clear cross-sell potential to wound care centers, hospitals, and post-acute care networks already using or evaluating enzymatic debridement products.

Burn Care Expansion NexoBrid is FDA-approved and commercially active in the US, EU, and Japan. Sellers can target burn centers, trauma facilities, and regional distributors to expand adoption, emphasizing regulatory approvals, demonstrated safety/efficacy, and improved outcomes for enzymatic eschar removal in thermal burn patients.

Global Market Readiness International marketing indicates readiness to scale; leverage distributor partnerships in key regions and tailor pricing, reimbursement, and education programs for different health systems to accelerate uptake in ambulatory surgical centers, specialty hospitals, and wound care clinics.

Clinical Validation Recent expert consensus and peer-reviewed support for biologically active debridement reinforce the value proposition of EscharEx and NexoBrid. Use these endorsements in case studies, thought leadership, and KOL engagement to unlock trial-driven conversions and payer conversations.

Financial Momentum Revenue guidance in the low tens of millions with ongoing losses suggests a need for strategic partnerships, bundled offerings, and early-access programs. Propose collaboration for co-marketing, co-development, or regional commercialization to accelerate revenue growth while mitigating market entry risk.